Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon

IF 2.8 3区医学 Q3 VIROLOGY

Virology Pub Date : 2025-02-25 DOI:10.1016/j.virol.2025.110467

Mehdi Benlarbi , Dell-Dylan Kenfack , Katrina Dionne , Maxime Côté-Chenette , Guillaume Beaudoin-Bussières , Étienne Bélanger , Shilei Ding , Oumarou H. Goni , Yannick F. Ngoume , Alexandra Tauzin , Halima Medjahed , Elodie Ghedin , Ralf Duerr , Andrés Finzi , Marcel Tongo

{"title":"Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon","authors":"Mehdi Benlarbi , Dell-Dylan Kenfack , Katrina Dionne , Maxime Côté-Chenette , Guillaume Beaudoin-Bussières , Étienne Bélanger , Shilei Ding , Oumarou H. Goni , Yannick F. Ngoume , Alexandra Tauzin , Halima Medjahed , Elodie Ghedin , Ralf Duerr , Andrés Finzi , Marcel Tongo","doi":"10.1016/j.virol.2025.110467","DOIUrl":null,"url":null,"abstract":"<div><div>In May 2023 the World Health Organization (WHO) declared the end of COVID-19 as a public health emergency. Seroprevalence studies performed in African countries, such as Cameroon, depicted a much higher COVID-19 burden than reported by the WHO. To better understand humoral responses kinetics following infection, we enrolled 333 participants from Yaoundé, Cameroon between March 2020 and January 2022. We measured the levels of antibodies targeting the SARS-CoV-2 receptor-binding-domain (RBD) and the Spike glycoproteins of Delta, Omicron BA.1 and BA.4/5 and the common cold coronavirus HCoV-OC43. We also evaluated plasma capacity to neutralize authentic SARS-CoV-2 virus and to mediate Antibody-Dependent Cellular Cytotoxicity (ADCC). Most individuals mounted a strong antibody response against SARS-CoV-2 Spike. Plasma neutralization waned faster than anti-Spike binding and ADCC. We observed differences in humoral responses by age and circulating variants. Altogether, we show a global overview of antibody dynamics and functionality against SARS-CoV-2 in Cameroon.</div></div>","PeriodicalId":23666,"journal":{"name":"Virology","volume":"605 ","pages":"Article 110467"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0042682225000790","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In May 2023 the World Health Organization (WHO) declared the end of COVID-19 as a public health emergency. Seroprevalence studies performed in African countries, such as Cameroon, depicted a much higher COVID-19 burden than reported by the WHO. To better understand humoral responses kinetics following infection, we enrolled 333 participants from Yaoundé, Cameroon between March 2020 and January 2022. We measured the levels of antibodies targeting the SARS-CoV-2 receptor-binding-domain (RBD) and the Spike glycoproteins of Delta, Omicron BA.1 and BA.4/5 and the common cold coronavirus HCoV-OC43. We also evaluated plasma capacity to neutralize authentic SARS-CoV-2 virus and to mediate Antibody-Dependent Cellular Cytotoxicity (ADCC). Most individuals mounted a strong antibody response against SARS-CoV-2 Spike. Plasma neutralization waned faster than anti-Spike binding and ADCC. We observed differences in humoral responses by age and circulating variants. Altogether, we show a global overview of antibody dynamics and functionality against SARS-CoV-2 in Cameroon.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Virology 医学-病毒学

CiteScore

6.00

自引率

0.00%

发文量

157

审稿时长

50 days

期刊介绍： Launched in 1955, Virology is a broad and inclusive journal that welcomes submissions on all aspects of virology including plant, animal, microbial and human viruses. The journal publishes basic research as well as pre-clinical and clinical studies of vaccines, anti-viral drugs and their development, anti-viral therapies, and computational studies of virus infections. Any submission that is of broad interest to the community of virologists/vaccinologists and reporting scientifically accurate and valuable research will be considered for publication, including negative findings and multidisciplinary work.Virology is open to reviews, research manuscripts, short communication, registered reports as well as follow-up manuscripts.